These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 16669977

  • 1. Long-term comparison of sevelamer hydrochloride to calcium-containing phosphate binders.
    Brewster UC, Ciampi MA, Abu-Alfa AK, Reilly RF.
    Nephrology (Carlton); 2006 Apr; 11(2):142-6. PubMed ID: 16669977
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
    Sturtevant JM, Hawley CM, Reiger K, Johnson DW, Campbell SB, Burke JR, Bofinger A, Isbel NM.
    Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
    [Abstract] [Full Text] [Related]

  • 3. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
    Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF.
    Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
    [Abstract] [Full Text] [Related]

  • 4. [The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients].
    Zwiech R, Dryja P, Łacina D, Króliczak V, Chrul S, Kacprzyk F.
    Wiad Lek; 2011 Oct; 64(1):9-14. PubMed ID: 21812357
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability.
    de Francisco AL, Leidig M, Covic AC, Ketteler M, Benedyk-Lorens E, Mircescu GM, Scholz C, Ponce P, Passlick-Deetjen J.
    Nephrol Dial Transplant; 2010 Nov; 25(11):3707-17. PubMed ID: 20530499
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.
    Evenepoel P, Selgas R, Caputo F, Foggensteiner L, Heaf JG, Ortiz A, Kelly A, Chasan-Taber S, Duggal A, Fan S.
    Nephrol Dial Transplant; 2009 Jan; 24(1):278-85. PubMed ID: 18820280
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy of combined sevelamer and calcium carbonate therapy for hyperphosphatemia in Japanese hemodialysis patients.
    Iwasaki Y, Takami H, Tani M, Yamaguchi Y, Goto H, Goto Y, Goto Y, Shigematsu T.
    Ther Apher Dial; 2005 Aug; 9(4):347-51. PubMed ID: 16076380
    [Abstract] [Full Text] [Related]

  • 9. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN, Lewis JB, Dwyer JP, Greene T, Middleton J, Sika M, Umanath K, Abraham JD, Arfeen SS, Bowline IG, Chernin G, Fadem SZ, Goral S, Koury M, Sinsakul MV, Weiner DE, Collaborative Study Group.
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [Abstract] [Full Text] [Related]

  • 10. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
    Prajapati VA, Galani VJ, Shah PR.
    Saudi J Kidney Dis Transpl; 2014 May; 25(3):530-8. PubMed ID: 24821148
    [Abstract] [Full Text] [Related]

  • 11. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management.
    Ogata H, Koiwa F, Shishido K, Kinugasa E.
    Ther Apher Dial; 2005 Feb; 9(1):11-5. PubMed ID: 15828900
    [Abstract] [Full Text] [Related]

  • 12. Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders.
    Noto L.
    J Ren Nutr; 2011 May; 21(3):277-82. PubMed ID: 20598905
    [Abstract] [Full Text] [Related]

  • 13. Long-term comparison of a calcium-free phosphate binder and calcium carbonate--phosphorus metabolism and cardiovascular calcification.
    Braun J, Asmus HG, Holzer H, Brunkhorst R, Krause R, Schulz W, Neumayer HH, Raggi P, Bommer J.
    Clin Nephrol; 2004 Aug; 62(2):104-15. PubMed ID: 15356967
    [Abstract] [Full Text] [Related]

  • 14. Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study).
    Qunibi WY, Hootkins RE, McDowell LL, Meyer MS, Simon M, Garza RO, Pelham RW, Cleveland MV, Muenz LR, He DY, Nolan CR.
    Kidney Int; 2004 May; 65(5):1914-26. PubMed ID: 15086935
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of sevelamer in the treatment of uncontrolled hyperphosphataemia of haemodialysis patients.
    Almirall J, Lopez T, Vallve M, Ruiz A, Llibre J, Betriu A.
    Nephron Clin Pract; 2004 May; 97(1):c17-22. PubMed ID: 15153763
    [Abstract] [Full Text] [Related]

  • 16. Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients.
    Gallieni M, Cozzolino M, Carpani P, Zoni U, Brancaccio D.
    J Nephrol; 2001 May; 14(3):176-83. PubMed ID: 11439741
    [Abstract] [Full Text] [Related]

  • 17. Oral phosphate binders for the management of serum phosphate levels in dialysis patients.
    Mohammed I, Hutchison AJ.
    J Ren Care; 2009 Mar; 35 Suppl 1():65-70. PubMed ID: 19222734
    [Abstract] [Full Text] [Related]

  • 18. Safety of new phosphate binders for chronic renal failure.
    Loghman-Adham M.
    Drug Saf; 2003 Mar; 26(15):1093-115. PubMed ID: 14640773
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.